Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Trial Profile

Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin (Primary) ; Eltrombopag (Primary)
  • Indications Anaemia; Aplastic anaemia; Neutropenia; Pancytopenia; Thrombocytopenia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Apr 2017 Primary endpoint (Rate of complete hematologic response at six months for cohort 3) has been met.
    • 20 Apr 2017 Primary endpoint (Rate of complete hematologic response at six months for cohort 2) has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top